Skip to main content

Overview

All information and news about Medincell stock (Euronext Paris: MEDCL)

Medincell share price

37.12€

0.8 / 2.2%

2025-10-28 17:37 (Paris)

Data provided by Euronext, in real time.

See stock quote, chart & historical on Euronext.com

Listed on

Euronext Paris /
B Compartment

ISIN code / Ticker

FR0004065605 /
MEDCL

Number of shares

33,098,886
(September 30, 2025)

Liquidity Provider

Rothschild Martin Maurel

Analyst coverage

Medincell is followed by the analysts listed. Please note that any opinions, estimates, or forecasts regarding Medincell’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Medincell or its management. Medincell does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions, or recommendations.

Company

Analyst

Contact

Evercore

Michael DiFiore

Truist Securities

Les Sulewski

H.C. Wainwright & Co.

Raghuram Selvaraju

Jefferies

Shan Hama

Stifel

Oscar Haffen Lamm

ODDO BHF

Martial Descoutures

Kepler Chevreux

Nicolas Pauillac

Portzamparc

Mohamed Kaabouni

TP ICAP

Claire Deray

Documentation

June 2025

Corporate presentation

2025

CSR report

Latest news

Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)
October 22, 2025

Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
October 10, 2025

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
September 23, 2025

Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®

New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®
September 22, 2025

New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®

New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
September 22, 2025

New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed

Investors contacts

Medincell

David Heuzé

Head of Corporate and Financial Communications, and ESG

Medincell

Grace Kim

Head of US Financial Strategy & IR

Investor relations

Louis-Victor Delouvrier
& Alban Dufumier

Newcap

Media

Nicolas Merigeau

Newcap